Recent news on Zydis

Lonnie Ali Champions 'Fight For MORE' Campaign  -  Apr 26, 2007
PR Newswire (press release),Valeant is the maker of Zelapar(R) (selegiline HCl), the first Parkinson's disease treatment to use a novel oral delivery system called Zydis(R) Technology,

LONNIE ALI CHAMPIONS "FIGHT FOR MORE" CAMPAIGN  -  26 Apr 2007
FPSnewswire (press release),Valeant is the maker of Zelapar(r) (selegiline HCl), the first Parkinson's disease treatment to use a novel oral delivery system called Zydis(r) Technology,

Several state qualifiers return  -  Apr 1, 2007
Adrian Daily Telegram,Junior Betsy Brown returns in the long jump and sprints, Kaitlyn Ballard in the high jump and sprints and Amanda Zydis in the distance races while Sarah

APR Applied Pharma Research sa and Labtec GmbH Announce Positive ...  -  Mar 1, 2007
PharmaLive.com (press release),The bioequivalence for the AUCs of Ondansetron 8mg RapidFilm™ versus Zofran® 8mg Zydis® ODT has was demonstrated by a pilot bioequivalence study.

Oral strip for generic Zofran  -  Mar 5, 2007
In-PharmaTechnologist.com,...with GlaxoSmithKline's (GSK) Zofran Zydis (ondansetron) orally dissolving tablets for the treatment of chemotherapy related nausea and vomiting.

Blackstone appoints George L. Fotiades and Alex Erdeljan to ...  -  Jan 29, 2007
Business Wire (press release),Its core offerings include the development and manufacture of oral and sterile medication, and the softgel and Zydis fast dissolving technologies.

Cardinal sells drug manufacturing biz and doubles Q2 profit  -  Jan 29, 2007
DrugResearcher.com,Among its core offerings, PTS develops and manufactures oral and sterile medication in nearly all dosage forms, and holds patents for Softgel and Zydis

Cardinal Health Enters $11Mln Settlement To Resolve NY Attorney ...  -  Dec 26, 2006
Trading Markets,Among its core offerings, it develops and manufactures oral and sterile medication in nearly all dosage forms, and holds patents for SOFTGEL and ZYDIS

Cardinal Health Enters $11Mln Settlement To Resolve NY Attorney ...  -  26 Dec 2006
Trading Markets,Among its core offerings, it develops and manufactures oral and sterile medication in nearly all dosage forms, and holds patents for SOFTGEL and ZYDIS

Cardinal Health Announces Plans to Sell $1.8 Billion ...  -  Nov 30, 2006
Drug Newswire (press release),Among its core offerings, it develops and manufactures oral and sterile medication in nearly all dosage forms, and holds patents for softgel and Zydis(R)

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional